524816

Natco Pharma Limited informed the exchanges about the enclosure of the transcript of its earnings conference call for Q4 FY25-26, which was held on May 29, 2026. The transcript is also available on the company's website.

Consolidated Revenue ₹739.1Cr vs ₹1,221.0Cr (▼39.5% YoY), EBITDA ₹127.6Cr vs ₹548.1Cr (▼76.7% YoY), PAT ₹269.0Cr vs ₹406.0Cr (▼33.7% YoY), with EBITDA Margin 15.62% vs 44.89% (▼2927bps); the Q4 PAT includes a one-time deferred tax asset benefit of ₹115.0Cr.

Consolidated Revenue from operations for Q4 FY26 was ₹739.1Cr vs ₹1,221.0Cr (▼39.5% YoY), EBITDA was ₹127.6Cr vs ₹548.1Cr (▼76.7% YoY), and PAT was ₹269.0Cr vs ₹406.0Cr (▼33.7% YoY). EBITDA Margin contracted from 44.9% to 17.3% (▼2760bps). The net profit for the quarter includes a one-time benefit of ₹115Cr from moving to a new tax regime and re-measuring deferred tax assets.

Natco Pharma Limited submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026, as per Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The report confirms overall compliance with applicable statutory provisions. It noted that some related party transactions lacked prior audit committee approval but were subsequently ratified by the Audit Committee and Board of Directors. The report also stated that no actions were taken against the company by SEBI or stock exchanges during the review period.